Improved methods of administering neurokinin-1 receptor antagonists, preferably fosnetupitant, via intravenous bolus, preferably over reduced periods of time.
The present invention is related to crystalline forms of 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is an NK-1 antagonist useful in the treatment of induced vomiting and other disorders.
The new compound 3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea monohydrochloride salt has a high capability to permeate through the blood-brain barrier and to display, at central nervous system level, a consistent ghrelin agonist activity; the compound is effective in the treatment and/or prevention of a medical condition mediated by the ghrelin receptor in the central nervous system. In particular, in experimental tests, the compound has shown high efficacy in the treatment of neurotoxic damage, with a useful combined pattern of neuroprotective effects both at central and peripheral level. The compound is further useful in the treatment of conditions which require a reduction of the heart rate. The compound is pharmacologically active at low to moderate doses, thus showing a favourable therapeutic index.
The invention concerns the use of compounds represented by formula (I) as inotropic agents. The compounds of formula (I), which include, as preferred, 1-[(1S)-1-(2,3-dichloro-4-methoxyphenypethyl]-3-methyl-3-[(4R)-1-methyl-3,3-dimethyl-4-piperidyl]-urea and its hydrochloride salt, are herein reported to have a significant inotropic activity on cardiomyocytes from both normal and myocardial infarction-induced heart failure animal models, which makes them useful for treating cardiovascular patients in need thereof. Differently from known inotropic agents, the present compounds are effective on cardiomyocyte contractility without influencing calcium mobilization. Accordingly, they are advantageously free from adverse effects caused by increased calcium concentrations, such as increased oxygen demand, tachycardia, arrhythmia, ischemia, etc. Overall, a new, safe and effective inotropic treatment is thus made available.
The invention concerns the use of compounds represented by formula (I) as inotropic agents. The compounds of formula (I), which include, as preferred, 1-[(1S)-1-(2,3-dichloro-4-methoxyphenypethyl]-3-methyl-3-[(4R)-1-methyl-3,3-dimethyl-4-piperidyl]-urea and its hydrochloride salt, are herein reported to have a significant inotropic activity on cardiomyocytes from both normal and myocardial infarction-induced heart failure animal models, which makes them useful for treating cardiovascular patients in need thereof. Differently from known inotropic agents, the present compounds are effective on cardiomyocyte contractility without influencing calcium mobilization. Accordingly, they are advantageously free from adverse effects caused by increased calcium concentrations, such as increased oxygen demand, tachycardia, arrhythmia, ischemia, etc. Overall, a new, safe and effective inotropic treatment is thus made available.
A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
5.
LIQUID ORAL FORMULATIONS OF NETUPITANT AND PALONOSETRON
Orally administered liquid formulations of netupitant and palonosetron that are efficacious, chemically stable and physiologically balanced for safety and efficacy.
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/00 - Medicinal preparations containing organic active ingredients
7.
Compositions and methods for treating centrally mediated nausea and vomiting
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/473 - QuinolinesIsoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
8.
Physiologically balanced injectable formulations of fosnetupitant
Injectable dosages and formulations of fosnetupitant and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy.
The new compound 3-(1-(2,3-dichloro-4-methoxyphenyl) ethyl)-1-methyl-1-(1,3, 3-trimethylpiperidin-4-yl)urea monohydrochloride salt has a high capability to permeate through the blood-brain barrier and to display, at central nervous system level, a consistent ghrelin agonist activity; the compound is effective in the treatment and/or prevention of a medical condition mediated by the ghrelin receptor in the central nervous system. In particular, in experimental tests, the compound has shown high efficacy in the treatment of neurotoxic damage, with a useful combined pattern of neuroprotective effects both at central and peripheral level. The compound is further useful in the treatment of conditions which require a reduction of the heart rate. The compound is pharmacologically active at low to moderate doses, thus showing a favourable therapeutic index.
Uses of anamorelin for improving patient reported outcomes in anorexia / cachexia patients, particularly based on patient populations who benefit from such use, and methods for defining and providing clinically meaningful treatment effects.
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
A61P 43/00 - Drugs for specific purposes, not provided for in groups
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
A61P 43/00 - Drugs for specific purposes, not provided for in groups
12.
Process for the synthesis of substituted chloromethyl dialkylphosphates
Disclosed are compounds including phosphate and N-oxide prodrugs of the NK1 antagonist netupitant, useful in the prevention and/or treatment of diseases including emesis induced by chemotherapy. Also disclosed are methods of making a di-tert-butyl (chloromethyl) phosphate useful in the manufacture of such prodrugs by reacting a dialkylphosphate salt with an acid to obtain the corresponding ester of phosphoric acid, reacting the ester with a quaternary ammonium hydroxide base to form a monobasic salt, and reacting the monobasic salt with chloroiodomethane to form the corresponding chloromethyl dialkyl phosphate.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
A61K 31/473 - QuinolinesIsoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 1/08 - Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigoAntiemetics
A61P 13/10 - Drugs for disorders of the urinary system of the bladder
C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
C07D 213/76 - Nitrogen atoms to which a second hetero atom is attached
C07D 213/89 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
14.
PIPERIDINE UREA DERIVATIVES FOR USE AS INOTROPIC AGENTS
The invention concerns the use of compounds represented by formula (I) as inotropic agents. The compounds of formula (I), which include, as preferred, 1-[(1S)-1- (2,3-dichloro-4-methoxyphenyl)ethyl]-3-methyl-3-[(4R)-1-methyl-3,3-dimethyl-4-piperidyl]-urea and its hydrochloride salt, are herein reported to have a significant inotropic activity on cardiomyocytes from both normal and myocardial infarction-induced heart failure animal models, which makes them useful for treating cardiovascular patients in need thereof. Differently from known inotropic agents, the present compounds are effective on cardiomyocyte contractility without influencing calcium mobilization. Accordingly, they are advantageously free from adverse effects caused by increased calcium concentrations, such as increased oxygen demand, tachycardia, arrhythmia, ischemia, etc. Overall, a new, safe and effective inotropic treatment is thus made available.
A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
15.
PIPERIDINE UREA DERIVATIVES FOR USE AS INOTROPIC AGENTS
The invention concerns the use of compounds represented by formula (I) as inotropic agents. The compounds of formula (I), which include, as preferred, 1-[(1S)-1- (2,3-dichloro-4-methoxyphenyl)ethyl]-3-methyl-3-[(4R)-1-methyl-3,3-dimethyl-4-piperidyl]-urea and its hydrochloride salt, are herein reported to have a significant inotropic activity on cardiomyocytes from both normal and myocardial infarction-induced heart failure animal models, which makes them useful for treating cardiovascular patients in need thereof. Differently from known inotropic agents, the present compounds are effective on cardiomyocyte contractility without influencing calcium mobilization. Accordingly, they are advantageously free from adverse effects caused by increased calcium concentrations, such as increased oxygen demand, tachycardia, arrhythmia, ischemia, etc. Overall, a new, safe and effective inotropic treatment is thus made available.
A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
16.
Fumarate salt of (R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea, methods of preparation, and uses thereof
Provided are various embodiments relating to fumarate salt of (R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl) urea, and methods of producing and using the same to treat conditions and disorders associated with an increase of ghrelin level, such as food abuse, alcohol addiction, and other disorders (e.g., Prader-Willi syndrome). Also provided are various embodiments relating to crystalline HM04 free base, different crystalline forms of HM04 fumarate salt, and methods of producing the same.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 5/06 - Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
17.
METHODS OF MANUFACTURING ANAMORELIN TABLETS HAVING IMPROVED STABILITY
Methods for reducing the formation of impurities in finished dosage forms of anamorelin hydrochloride, including formulations for improving such stability and analytical techniques for controlling impurity formation.
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
36 - Financial, insurance and real estate services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
advice to patients regarding business administration of pharmacy reimbursement programs financial advice to patients regarding financial reimbursement of medicines pharmaceutical advice to patients regarding medicine choice in medication reimbursement programs
19.
METHODS OF USING 4-AMINO-N-[4-(METHOXYMETHYL)PHENYL]-7-(1-METHYLCYCLOPROPYL)-6-(3-MORPHOLINOPROP-1-YN-1-YL)-7H-PYRROLO[2,3-D]PYRIMIDINE-5-CARBOXAMIDE FOR THE TREATMENT OF TUMORS
The present invention relates to compositions and methods for treating patients with cancer having a RET gene abnormality comprising administering HM06/TAS0953, for example patients with non-small cell lung cancer (NSCLC), and that may also have brain and/or leptomeningeal metastases, or another solid tumor; where the patient is administered an effective amount of HM06/TAS0953, where the HM06/TAS0953 can be formulated in a composition and administered orally in a single or multiple doses; and where the patients may have previously received and/or have developed resistance to another RET-selective or multi-kinase inhibitor.
A61P 35/04 - Antineoplastic agents specific for metastasis
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
20.
CRYSTALLINE FORMS OF 4-AMINO-N-[4-(METHOXYMETHYL)PHENYL]-7-(1-METHYLCYCLOPROPYL)-6-(3-MORPHOLINOPROP-1-YN-1-YL)-7H-PYRROLO[2,3-D]PYRIMIDINE-5-CARBOXAMIDE, METHODS OF PREPARATION, AND USES THEREOF
Provided herein are various crystalline forms of 4-amino-N-[4-(methoxymethyl)phenyl]-7-(1- methylcyclopropyl)-6-(3-morpholinoprop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5- carboxamide, methods of producing same, and methods of using same to for RET inhibition.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of cachexia and cancer-associated anorexia, weight loss and erosion of body mass, abnormalities of metabolism; veterinary preparations for the treatment of cachexia and cancer-associated anorexia, weight loss and erosion of body mass, abnormalities of metabolism, sanitary preparations for medical use; dietetic foods, namely, nutritional liquid and solid support in the nature of nutritional supplements in liquid and solid form adapted for medical or veterinary use; dietetic substances, namely, nutritional liquid and solid support in the nature of nutritional supplements in liquid and solid form for medical or veterinary use
The present invention is related to crystalline forms of 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is an NK-1 antagonist useful in the treatment of induced vomiting and other disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, namely, anti-inflammatory
drugs, anti-emetic drugs, drugs for the treatment of cancer,
carcinoma, leukemia, lymphoma, melanoma; anti-tumor drugs
and anticancer drugs; pharmaceutical preparations for the
treatment of oncological diseases and the side effects of
treatment; pharmaceutical preparations for the treatment of
ulcerative and inflammatory conditions, anti-anxiety drugs,
anti-migraine drugs, cognition enhancing drugs, drugs for
the prevention and treatment of gastroenterological,
hepatologic, nephrologic and cardiovascular disorders of any
origin; pharmaceutical preparations for internal cleansing
purposes, bowel cleansers and evacuants for medical and
pharmaceutical use; veterinary vaccines and sanitary
preparations for medical use; dietetic foods for medical
use, food for babies; medical and surgical plasters,
materials for dressings, namely bandages; material for
dental fillings and dental impressions; disinfectants for
sanitary and hygiene use; products for destroying vermin;
fungicides, herbicides.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations and substances for the treatment
of cancer and skeletal abnormalities. Conducting research and development in the fields of cancer
and skeletal abnormalities.
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/473 - QuinolinesIsoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/00 - Medicinal preparations containing organic active ingredients
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Préparations pharmaceutiques pour le traitement de lymphomes, de lymphomes non hodgkiniens, de lymphomes cutanés à cellules T, de mycoses fongoïdes, de vitiligos, de psoriasis, d'alopécies circonscrites, d'une histiocytose, de mélanomes et de maladies auto-immunes de la peau.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of cachexia and cancer-associated anorexia, weight loss and erosion of body mass, abnormalities of metabolism; and veterinary preparations for the treatment of cachexia and cancer-associated anorexia, weight loss and erosion of body mass, abnormalities of metabolism; hygienic products for medicine, namely, disinfectants; food and drink, namely, dietetic foods adapted for medical or veterinary use and medicinal drinks; dietetic substances, namely, food and drink adapted for medical or veterinary use; baby food; dietary supplements for human and animal food; medical and surgical plasters; medical and surgical dressing materials; dental impression materials; disinfectants; products for the destruction of animals pests, namely, insect repellent and granular repellent for burrowing pests; fungicides, herbicides; sanitary preparations for medical use; dietetic foods, namely, nutritional liquid and solid support adapted for medical or veterinary use; dietetic substances, namely, nutritional liquid beverages and solid food support for medical or veterinary use; food supplements for humans and animals
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of cachexia and cancer-associated anorexia, weight loss and erosion of body mass, abnormalities of metabolism; and veterinary preparations for the treatment of cachexia and cancer-associated anorexia, weight loss and erosion of body mass, abnormalities of metabolism; hygienic products for medicine, namely, disinfectants; food and drink, namely, dietetic foods adapted for medical or veterinary use and medicinal drinks; dietetic substances, namely, food and drink adapted for medical or veterinary use; baby food; dietary supplements for human and animal food; medical and surgical plasters; medical and surgical dressing materials; dental impression materials; disinfectants; products for the destruction of animals pests, namely, insect repellent and granular repellent for burrowing pests; fungicides, herbicides; sanitary preparations for medical use; dietetic foods, namely, nutritional liquid and solid support adapted for medical or veterinary use; dietetic substances, namely, nutritional liquid beverages and solid food support for medical or veterinary use; food supplements for humans and animals
34.
METHODS OF MANUFACTURING ANAMORELIN TABLETS HAVING IMPROVED STABILITY
Methods for reducing the formation of impurities in finished dosage forms of anamorelin hydrochloride, including formulations for improving such stability and analytical techniques for controlling impurity formation.
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4427 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 213/89 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
A61P 1/08 - Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigoAntiemetics
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
Goods & Services
Organisation of conferences and symposia in the field of medical science and specifically CINV (chemotherapy-indiced nausea and vomiting); arranging of educational conferences in the field of medical science and specifically CINV (chemotherapy-indiced nausea and vomiting); arranging of educational events in the field of medical science and specifically CINV (chemotherapy-indiced nausea and vomiting); arranging of educational seminars events in the field of medical science and specifically CINV (chemotherapy-indiced nausea and vomiting); providing continuing medical education courses events in the field of medical science and specifically CINV (chemotherapy-indiced nausea and vomiting). Scientific and technological services and research and design relating thereto; consultancy in the field of pharmacology.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations and substances for the treatment of cancer
39.
Fumarate salt of (R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2- trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl) urea, methods of preparation, and uses thereof
Provided are various embodiments relating to fumarate salt of (R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl) urea, and methods of producing and using the same to treat conditions and disorders associated with an increase of ghrelin level, such as food abuse, alcohol addiction, and other disorders (e.g., Prader-Willi syndrome). Also provided are various embodiments relating to crystalline HM04 free base, different crystalline forms of HM04 fumarate salt, and methods of producing the same.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 5/06 - Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
40.
CONTINUOUS PROCESS FOR PRODUCING BENZIMIDAZOLE DERIVATIVES
Disclosed are continuous processes for producing benzimidazole derivative Compound 1 comprising reduction of Compound 2 and reaction with valeraldehyde and conditions and apparatuses for the same.
C07D 233/61 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
41.
Methods of producing anamorelin hydrochloride having controlled chloride content
The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms.
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07K 5/062 - Dipeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
The present invention is related to crystalline forms of 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is an NK-1 antagonist useful in the treatment of induced vomiting and other disorders.
Injectable dosages and formulations of fosnetupitant and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products, medical and veterinary
preparations; sanitary products for medical purposes;
dietetic substances and foodstuffs for medical or veterinary
use, food for babies; food supplements for humans and
animals; plasters, materials for dressings; material for
dental fillings and dental impressions; disinfectants;
products for destroying vermin; fungicides, herbicides.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products, namely, anti-inflammatory drugs, anti-emetic drugs, drugs for the treatment of cancer, carcinoma, leukemia, lymphoma, melanoma, tumors oncological diseases and the side effects of treatment, ulcerative and inflammatory conditions, antianxiety drugs, anti-migraine drugs, cognition enhancing drugs, drugs for the prevention and treatment of gastroenterological, hepatologic, nephrologic and cardiovascular disorders of any origin; pharmaceutical preparations for internal cleansing purposes, bowel cleansers and evacuants for medical and pharmaceutical purposes; medical and veterinary preparations for medical use for the treatment of cancer, carcinoma, leukemia, lymphoma, melanoma, tumors oncological diseases and the side effects of treatment, ulcerative and inflammatory conditions, antianxiety drugs, anti-migraine drugs, cognition enhancing drugs, drugs for the prevention and treatment of gastroenterological, hepatologic, nephrologic and cardiovascular disorders of any origin; sanitary preparations for medical purposes; dietetic foods and beverages for medical or veterinary use; food for babies; food supplements for humans and animals; medical and surgical plasters; materials for dressings in the nature of bandages; material for dental fillings and dental impressions; disinfectants; preparations for destroying vermin; fungicides; herbicides
49.
NEW CENTRALLY-ACTIVE GHRELIN AGONIST AND MEDICAL USES THEREOF
The new compound 3-(1-(2,3-dichloro-4-methoxyphenyl) ethyl)-1 -methyl-1 -(1,3, 3- trimethylpiperidin -4-yl)urea monohydrochloride salt has a high capability to permeate through the blood-brain barrier and to display, at central nervous system level, a consistent ghrelin agonist activity; the compound is effective in the treatment and/or prevention of a medical condition mediated by the ghrelin receptor in the central nervous system. In particular, in experimental tests, the compound has shown high efficacy in the treatment of neurotoxic damage, with a useful combined pattern of neuroprotective effects both at central and peripheral level. The compound is further useful in the treatment of conditions which require a reduction of the heart rate. The compound is pharmacologically active at low to moderate doses, thus showing a favourable therapeutic index.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
50.
NEW CENTRALLY-ACTIVE GHRELIN AGONIST AND MEDICAL USES THEREOF
The new compound 3-(1-(2,3-dichloro-4-methoxyphenyl) ethyl)-1 -methyl-1 -(1,3, 3- trimethylpiperidin -4-yl)urea monohydrochloride salt has a high capability to permeate through the blood-brain barrier and to display, at central nervous system level, a consistent ghrelin agonist activity; the compound is effective in the treatment and/or prevention of a medical condition mediated by the ghrelin receptor in the central nervous system. In particular, in experimental tests, the compound has shown high efficacy in the treatment of neurotoxic damage, with a useful combined pattern of neuroprotective effects both at central and peripheral level. The compound is further useful in the treatment of conditions which require a reduction of the heart rate. The compound is pharmacologically active at low to moderate doses, thus showing a favourable therapeutic index.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 25/00 - Drugs for disorders of the nervous system
A61P 9/00 - Drugs for disorders of the cardiovascular system
51.
HELSINN Helsinn Advanced Synthesis Where passion, reliability and quality meet
05 - Pharmaceutical, veterinary and sanitary products
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical products; chemical preparations for medical
use; chemical preparations for pharmaceutical use;
chemical-pharmaceutical preparations. Custom manufacture of pharmaceutical products per customer
order and in accordance with customer requirements. Research and development of pharmaceutical products;
scientific research in the field of chemical technologies;
scientific research in the field of pharmaceutical
technologies; engineering, including expertise in the field
of chemical and pharmaceutical technologies; technical
research; quality assessment; chemical analysis; research
in the field of chemistry; chemistry services; biological
research; conducting of quality control tests; surveying
(engineering work); testing of materials; research in the
field of physics; scientific and industrial research for
the development of medicines and active ingredients; advice
in the field of chemical research; industrial research in
the field of chemistry; industrial research in the field of
pharmaceutical technologies; advice in the field of
pharmaceutical technologies.
52.
Methods of producing anamorelin hydrochloride having controlled chloride content
The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms.
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07K 5/062 - Dipeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
FUMARATE SALT OF (R)-3-(1-(2,3-DICHLORO-4-(PYRAZIN-2-YL)PHENYL)-2,2,2-TRIFLUOROETHYL)-1-METHYL-1-(1-METHYLPIPERIDIN-4-YL) UREA, METHODS OF PREPARATION, AND USES THEREOF
Provided are various embodiments relating to fumarate salt of (R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl) urea, and methods of producing and using the same to treat conditions and disorders associated with an increase of ghrelin level, such as food abuse, alcohol addiction, and other disorders (e.g., Prader-Willi syndrome). Also provided are various embodiments relating to crystalline HM04 free base, different crystalline forms of HM04 fumarate salt, and methods of producing the same.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
54.
FUMARATE SALT OF (R)-3-(1-(2,3-DICHLORO-4-(PYRAZIN-2-YL)PHENYL)-2,2,2-TRIFLUOROETHYL)-1-METHYL-1-(1-METHYLPIPERIDIN-4-YL) UREA, METHODS OF PREPARATION, AND USES THEREOF
Provided are various embodiments relating to fumarate salt of (R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl) urea, and methods of producing and using the same to treat conditions and disorders associated with an increase of ghrelin level, such as food abuse, alcohol addiction, and other disorders (e.g., Prader-Willi syndrome). Also provided are various embodiments relating to crystalline HM04 free base, different crystalline forms of HM04 fumarate salt, and methods of producing the same.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 25/30 - Drugs for disorders of the nervous system for treating abuse or dependence
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
55.
Substituted piperaziniums for the treatment of emesis
C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 213/89 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
A61P 1/08 - Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigoAntiemetics
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/00 - Medicinal preparations containing organic active ingredients
The present invention is related to crystalline forms of 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is an NK-1 antagonist useful in the treatment of induced vomiting and other disorders.
40 - Treatment of materials; recycling, air and water treatment,
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Custom manufacture of pharmaceutical products per customer order and in accordance with customer requirements A full line of pharmaceuticals in the field of supportive cancer care; pharmaceutical preparations, namely, anti-inflammatory drugs, antiemetic drugs, drugs for the treatment of cancer, carcinoma, leukemia, lymphoma, melanoma, anti-tumor drugs, anti-emetic, anti-tumor and anticancer pharmaceutical preparations for the treatment of oncological diseases and the side effects of treatment; drugs for use in case of ulcerative and inflammatory conditions, anti-anxiety drugs, anti-migraine drugs, cognition enhancing drugs, drugs for the prevention and treatment of gastroenterological, hepatologic, nephrologic and cardiovascular disorders of any origin; drugs for internal cleansing purposes, bowel cleansers and evacuants for medical and pharmaceuticals purposes, veterinary vaccines and sanitary preparations for medical use; dietetic foods adapted for medical use, food for babies; medical and surgical plasters, materials for dressings in the nature of bandages; materials for stopping teeth, dental wax; disinfectants for sanitary and hygiene purposes; preparations for destroying vermin; fungicides, herbicides Research and development of pharmaceutical products; scientific and industrial research for the development of medicines and active ingredients; chemistry services, namely, consultancy in the field of chemical and pharmaceutical technology; engineering services, including expertise in the field of chemical and pharmaceutical technology
60.
HELSINN ADVANCED SYNTHESIS WHERE PASSION, RELIABILITY AND QUALITY MEET
05 - Pharmaceutical, veterinary and sanitary products
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
Goods & Services
pharmaceuticals; chemical preparations for medical purposes; chemical preparations for pharmaceutical purposes; chemico-pharmaceutical preparations. manufacturing for others of pharmaceuticals. Research and development of pharmaceutical preparations; scientific research in the field of chemical technology; scientific research in the field of pharmaceutical technology; engineering; including expertise in the field of chemical and pharmaceutical technology; technical research; quality evaluation; chemical analysis; chemical research; chemical services; biological research; quality testing; surveying; material testing; physics [research]; research and development [for others] for the development of medicines and active substances; consulting in the field of chemical research; industrial research in the field of chemical research; industrial research in the field of pharmaceutical technology; consulting in the field of pharmaceutical technology.
Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general Formula I:
or pharmaceutically acceptable salts thereof.
C07D 211/58 - Nitrogen atoms attached in position 4
C07F 7/08 - Compounds having one or more C—Si linkages
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 239/26 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 211/60 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 211/94 - Oxygen atom, e.g. piperidine N-oxide
C07D 213/00 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
C07D 241/12 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
09 - Scientific and electric apparatus and instruments
Goods & Services
downloadable application software for monitoring and managing the side effects of pharmacological therapies in cancer patients; and downloadable computer software applications for monitoring and managing the side effects of pharmacological therapies in cancer patients
66.
Methods of producing anamorelin hydrochloride having controlled chloride content
The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms.
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07K 5/062 - Dipeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations namely anti-cachexia and anti-metabolic disturbances drugs, namely anti-inflammatories, and drugs for cancer cachexia, wasting syndrome, anorexia, fatigue, muscle wasting and sarcopenia.
68.
Compositions and methods for treating centrally mediated nausea and vomiting
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/473 - QuinolinesIsoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present invention is related to crystalline forms of 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is an NK-1 antagonist useful in the treatment of induced vomiting and other disorders.
C07D 213/75 - Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
70.
Solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-IUM-(fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone as a neurokinin receptor modulator
Disclosed is a solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium (fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone and its application in methods for preventing acute and delayed nausea and vomiting in a human patient receiving highly emetogenic cancer chemotherapy.
C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
C07D 453/02 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
C07J 9/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 213/89 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general formula (I):
C07D 211/58 - Nitrogen atoms attached in position 4
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 211/60 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 211/94 - Oxygen atom, e.g. piperidine N-oxide
A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Injectable dosages and formulations of fosnetupitant and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy.
Injectable dosages and formulations of fosnetupitant and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy.
Injectable dosages and formulations of fosnetupitant and pharmaceutically acceptable salts thereof are provided that are efficacious, chemically stable and physiologically balanced for safety and efficacy.
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/00 - Medicinal preparations containing organic active ingredients
05 - Pharmaceutical, veterinary and sanitary products
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
45 - Legal and security services; personal services for individuals.
Goods & Services
Pharmaceutical products, veterinary products; sanitary
products for medical purposes; dietetic substances for
medical use, food for babies; plasters, materials for
dressings; material for dental fillings and dental
impressions; disinfectants; products for destroying
vermin; fungicides, herbicides. Treatment and transformation of pharmaceutical products for
others. Research and development of pharmaceutical products,
scientific and industrial research for the development of
medicines and active ingredients, as well as consultancy in
the field of chemical and pharmaceutical technology;
engineering services, including expertise in the field of
chemical and pharmaceutical technology. Reviewing standards and practices to ensure compliance with
pharmaceutical laws and rules, and consultancy relating to
regulatory compliance in the pharmaceutical field;
licensing of intellectual property in the field of chemical
and pharmaceutical technology; exploitation of intellectual
property rights, particularly licensing of intellectual
property, including know-how in the field of chemical and
pharmaceutical technology.
78.
BENZENESULFONYL-ASYMMETRIC UREAS AND MEDICAL USES THEREOF
New benzenesulfonyl asymmetric ureas are herein disclosed, corresponding to the general formulas (I) –(IV) and pharmaceutically acceptable salts thereof, whose structure and substituents are detailed in the specification. Procedures for the synthesis of these compounds are disclosed. The compounds are active on the ghrelin receptors, in particular they have inverse agonist activity; they are useful in preventing and/or treating diseases pathophysiologically mediated by the ghrelin receptor, like e.g. obesity, diabetes and substance abuse. Also disclosed are pharmaceutical compositions comprising a compound as herein defined and a pharmaceutically acceptable carrier or vehicle.
C07C 311/00 - Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
C07D 239/26 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07C 317/14 - SulfonesSulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
C07C 317/26 - SulfonesSulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Medicated and non-medicated preparations in the form of
tablets, mucoadhesive tablets, compressed tablets, drops and
gels for the treatment of xerostomia.
80.
BENZENESULFONYL-ASYMMETRIC UREAS AND MEDICAL USES THEREOF
New benzenesulfonyl asymmetric ureas are herein disclosed, corresponding to the general formulas (I) (IV) and pharmaceutically acceptable salts thereof, whose structure and substituents are detailed in the specification. Procedures for the synthesis of these compounds are disclosed. The compounds are active on the ghrelin receptors, in particular they have inverse agonist activity; they are useful in preventing and/or treating diseases pathophysiologically mediated by the ghrelin receptor, like e.g. obesity, diabetes and substance abuse. Also disclosed are pharmaceutical compositions comprising a compound as herein defined and a pharmaceutically acceptable carrier or vehicle.
C07C 311/00 - Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
C07C 317/14 - SulfonesSulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
C07C 317/26 - SulfonesSulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
C07D 239/26 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
81.
Benzenesulfonyl-asymmetric ureas and medical uses thereof
C07D 209/08 - IndolesHydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
C07D 213/34 - Sulfur atoms to which a second hetero atom is attached
C07D 213/76 - Nitrogen atoms to which a second hetero atom is attached
C07D 215/06 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
C07D 215/08 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
C07D 215/58 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
C07D 217/04 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ringAlkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
C07D 233/64 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
C07D 235/14 - Radicals substituted by nitrogen atoms
C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 241/12 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 295/088 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07C 317/14 - SulfonesSulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
C07D 239/26 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07C 317/26 - SulfonesSulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
C07C 317/44 - SulfonesSulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Medicated preparations and food supplements in the form of
tablets, muco-adhesive tablets, compressed tablets, drops
and gels for xerostomia treatment.
40 - Treatment of materials; recycling, air and water treatment,
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
45 - Legal and security services; personal services for individuals.
Goods & Services
Treatment and transformation of chemical, biochemical and pharmaceutical products during the manufacture of pharmaceutical products for others Pharmaceutical preparations, namely, anti-inflammatory drugs, antiemetic drugs, drugs for the treatment of cancer, carcinoma, leukemia, lymphoma, melanoma, anti-tumor drugs, anti-emetic, anti-tumor and anticancer pharmaceutical preparations for the treatment of oncological diseases and the side effects of treatment; drugs for use in case of ulcerative and inflammatory conditions, anti-anxiety drugs, anti-migraine drugs, cognition enhancing drugs, drugs for the prevention and treatment of gastroenterological, hepatologic, nephrologic and cardiovascular disorders of any origin; drugs for internal cleansing purposes, bowel cleansers and evacuants for medical and pharmaceutical purposes, veterinary vaccines and sanitary preparations for medical use; dietetic foods adapted for medical use, food for babies; medical and surgical plasters, materials for dressings in the nature of bandages; material for stopping teeth, dental wax; disinfectants for sanitary and hygiene purposes; preparations for destroying vermin; fungicides, herbicides Research and development of pharmaceutical products; scientific and industrial research for the development of medicines and active ingredients; consultancy in the field of chemical and pharmaceutical technology; engineering services, including expertise in the field of chemical and pharmaceutical technology Reviewing standards and practices to assure compliance with pharmaceutical laws and regulations, regulatory compliance consulting to ensure compliance with public sector procurement and regulations in the field of chemical, biochemical pharmaceuticals and procurement in the field of chemical, biochemical pharmaceuticals and legal consultancy, in particular before and during national proceedings in the field of regulation of chemical, biochemical and pharmaceutical products licensing of intellectual property in the field of chemical, biochemical and pharmaceutical technologies and Licensing in the field of chemical, biochemical and pharmaceutical products; exploitation of intellectual property rights, particularly licensing of intellectual property including know-how in the field of chemical, biochemical and pharmaceutical technologies
84.
Substituted asymmetric ureas as modulators of ghrelin receptor activity
Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general Formula I:
or pharmaceutically acceptable salts thereof.
A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
C07C 275/26 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
C07F 7/08 - Compounds having one or more C—Si linkages
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 211/58 - Nitrogen atoms attached in position 4
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 239/26 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 211/60 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 211/94 - Oxygen atom, e.g. piperidine N-oxide
C07D 213/00 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
C07D 241/12 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A method is provided herein for making crystalline Form I fosnetupitant, characterized by an X-ray powder diffraction pattern comprising at least three peaks, in terms of 20, selected from the group consisting of 4.5, 9.0, 12.7, 13.5, 16.3, and 17.9 0.2 . The method comprises the steps of: (a) contacting the chloride hydrochloride salt of fosnetupitant with methylacetate and methanol to form a first liquid; (b) separating the methylacetate and methanol from the chloride hydrochloride salt of fosnetupitant of step (a); (c) contacting the chloride hydrochloride salt of fosnetupitant from step (b) with heptane to form a second liquid; and (d) evaporating said heptane from the said chloride hydrochloride salt of fosnetupitant of step (c).
The present invention provides crystalline forms of the chloride monohydrochloride salt of fosnetupitant, formula (I), methods of making the crystalline forms, and pharmaceutical dosage forms that make use of the crystalline forms.
The present invention provides crystalline forms of the chloride monohydrochloride salt of fosnetupitant, methods of making the crystalline forms, and pharmaceutical dosage forms that make use of the crystalline forms.
The invention relates to therapeutic uses of elsiglutide, particularly for protecting and stimulating bone marrow and peripheral blood cell type activity or immune-response in patients compromised due to the administration ofchemotherapeutic agents. The invention further provides uses of elsiglutide to enhance the antitumor activity of cytotoxic chemotherapeutic agents and target specific biological agents.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
35 - Advertising and business services
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
45 - Legal and security services; personal services for individuals.
Goods & Services
Chemical substances, chemical materials and chemical
products. Pharmaceutical products, veterinary products; sanitary
products for medical purposes; dietetic substances for
medical use. The bringing together, for the benefit of others, of a
variety of goods, namely chemical substances, chemical
materials and chemical products, pharmaceutical and
veterinary products, sanitary products for medical purposes,
dietetic substances for medical use, (excluding the
transport thereof) enabling consumers and wholesalers to
conveniently view and purchase those goods. Treatment and processing of chemical, biochemical and
pharmaceutical products for third parties; consulting
services relating to the treatment of chemical, biochemical
and pharmaceutical products; information and advisory
services in the field of chemical, biochemical and
pharmaceutical product treatment and processing. Scientific research and design services; technical and
scientific consultancy in the field of chemical, biochemical
and pharmaceutical products; scientific and industrial
research and consultations in the field of chemical,
biochemical and pharmaceutical technology; engineering
including engineering expertise in the field of chemical,
biochemical and pharmaceutical technology; provision of
technological professional knowledge, particularly in the
field of chemical, biochemical and pharmaceutical products
(franchising). Licensing in the field of chemical, biochemical and
pharmaceutical products; legal representation and advice,
particularly before and during national procedures for the
regulation of chemical, biochemical and pharmaceutical
products.
90.
Substituted piperaziniums for the treatment of emesis
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/4427 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems
C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 213/89 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
36 - Financial, insurance and real estate services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
advice to patients regarding business administration of pharmacy reimbursement programs financial advice to patients regarding financial reimbursement of medicines pharmaceutical advice to patients regarding medicine choice in medication reimbursement programs
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, namely, antiemetic drugs, anti-emetic, anti-tumor and anticancer pharmaceutical preparations for the treatment of oncological diseases and the side effects of treatment
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
pharmaceutical preparations for the prevention and treatment of chemotherapy and radiotherapy side effects Scientific research and development of medical devices, food supplements, dietary foods, nutraceuticals; development of pharmaceutical preparations and medicines
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Medicated and non-medicated preparations in the form of tablets, mucoadhesive tablets, compressed tablets, drops and gels for the treatment of xerostomia.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Food supplements consisting of cranberry extract for the prevention of urinary tract infections and urinary symptoms during radiotherapy for prostate carcinoma
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations and compositions for the treatment and prevention of cancer; biological preparations for the treatment of cancer; pain relief preparations; anti-inflammatories; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; nutritional supplements. Scientific research for medical purposes in the area of cancerous diseases. Providing cancer screening services; medical analysis services for cancer diagnosis and prognosis; providing information in the field of cancer prevention, screening, diagnosis and treatment.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products, medical and veterinary
preparations; medicines; pharmaceutical preparations and
substances; anti-emetic medicines; sanitary products for
medical purposes; dietetic food and substances for medical
or veterinary use, food for babies; food supplements for
humans and animals; plasters, materials for dressings;
material for dental fillings and dental impressions;
disinfectants; products for destroying vermin; fungicides,
herbicides.
40 - Treatment of materials; recycling, air and water treatment,
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
35 - Advertising and business services
42 - Scientific, technological and industrial services, research and design
45 - Legal and security services; personal services for individuals.
Goods & Services
Treatment in the nature of chemical processing of chemical, biochemical and pharmaceutical products for third parties [ ; consulting services relating to the treatment of chemical, biochemical and pharmaceutical products; information and advisory services in the field of chemical, biochemical and pharmaceutical products treatment and processing ] [ Chemical substances, namely, chemical compounds for analyses in laboratories for scientific purposes, other than for medical or veterinary use ] Pharmaceutical products, namely, anti-inflammatory drugs, antiemetic drugs, [ drugs for the treatment of cancer, carcinoma, leukemia, lymphoma, melanoma, anti-tumor drugs, ] anti-emetic, anti-tumor and anticancer pharmaceutical preparations for the treatment of oncological diseases and the side effects of treatment [ ; drugs for use in case of ulcerative and inflammatory conditions, anti-anxiety drugs, anti-migraine drugs, cognition enhancing drugs, drugs for the prevention and treatment of gastroenterological, hepatologic, nephrologic and cardiovascular disorders of any origin; drugs for internal cleansing purposes, bowel cleansers and evacuants for medical and pharmaceutical purposes, veterinary vaccines and sanitary preparations for medical purposes; dietetic foods adapted for medical use ] [ The bringing together, for the benefit of others, of a variety of goods, namely, chemical substances, chemical materials and chemical products, pharmaceutical products, sanitary products for medical purposes, dietetic substances for medical use, excluding the transport thereof, enabling customers and wholesalers to conveniently view and purchase those goods ] Scientific research and development of pharmaceuticals; scientific and industrial research for the development of drugs and chemical components [ , as well as technical and scientific consultancy in the fields of scientific research of chemical, biochemical and pharmaceutical technologies; engineering services including engineering surveys in the fields of chemical, biochemical and pharmaceutical technologies; provision of technological professional knowledge, particularly in the field of planning and design of technological development in franchising chemical, biochemical and pharmaceutical products ] Licensing in the field of chemical, biochemical and pharmaceutical products [ ; legal representation and advice, particularly before and during national procedures for the regulation of chemical, biochemical and pharmaceutical products ]
100.
Methods of producing anamorelin hydrochloride having controlled chloride content
The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07K 5/062 - Dipeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
